Abeona Therapeutics Inc./$ABEO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Ticker
$ABEO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
136
Website
ABEO Metrics
BasicAdvanced
$326M
-
-$0.95
1.55
-
Price and volume
Market cap
$326M
Beta
1.55
52-week high
$7.32
52-week low
$3.93
Average daily volume
982K
Financial strength
Current ratio
4.9
Quick ratio
4.77
Long term debt to equity
36.757
Total debt to equity
57.921
Interest coverage (TTM)
-16.36%
Profitability
EBITDA (TTM)
-67.561
Management effectiveness
Return on assets (TTM)
-49.95%
Return on equity (TTM)
-271.78%
Valuation
Price to book
7.53
Price to tangible book (TTM)
7.53
Price to free cash flow (TTM)
-4.718
Free cash flow yield (TTM)
-21.19%
Free cash flow per share (TTM)
-1.35
Growth
Earnings per share change (TTM)
-70.38%
3-year earnings per share growth (CAGR)
-64.10%
10-year earnings per share growth (CAGR)
-37.87%
Bulls say / Bears say
Abeona Therapeutics secured FDA approval for ZEVASKYN™, the first and only autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), positioning the company as a leader in this niche market. (globenewswire.com)
The company completed the sale of its Rare Pediatric Disease Priority Review Voucher for $155 million, bolstering its financial position and providing over two years of operating capital without the need for additional funding. (nasdaq.com)
Oppenheimer initiated coverage of Abeona Therapeutics with an 'Outperform' recommendation, reflecting confidence in the company's growth prospects and potential for significant stock appreciation. (nasdaq.com)
The reliance on the sale of a Priority Review Voucher for substantial funding may indicate a lack of sustainable revenue sources, raising concerns about long-term financial stability. (nasdaq.com)
Abeona received a Complete Response Letter from the FDA in April 2024, highlighting deficiencies in Chemistry Manufacturing and Controls (CMC) requirements, which could signal potential challenges in regulatory compliance and product approval processes. (businesswire.com)
Insider transactions, such as the CEO selling 25,000 shares in March 2025, might be perceived negatively by investors, potentially indicating a lack of confidence in the company's future performance. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abeona Therapeutics Inc. stock?
Abeona Therapeutics Inc. (ABEO) has a market cap of $326M as of August 01, 2025.
What is the P/E ratio for Abeona Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Abeona Therapeutics Inc. (ABEO) stock is 0 as of August 01, 2025.
Does Abeona Therapeutics Inc. stock pay dividends?
No, Abeona Therapeutics Inc. (ABEO) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Abeona Therapeutics Inc. dividend payment date?
Abeona Therapeutics Inc. (ABEO) stock does not pay dividends to its shareholders.
What is the beta indicator for Abeona Therapeutics Inc.?
Abeona Therapeutics Inc. (ABEO) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.